- Polsinelli, Angelina J;
- Wonderlin, Ryan J;
- Hammers, Dustin B;
- Garcia, Alex Pena;
- Eloyan, Ani;
- Taurone, Alexander;
- Thangarajah, Maryanne;
- Beckett, Laurel;
- Gao, Sujuan;
- Wang, Sophia;
- Kirby, Kala;
- Logan, Paige E;
- Aisen, Paul;
- Dage, Jeffrey L;
- Foroud, Tatiana;
- Griffin, Percy;
- Iaccarino, Leonardo;
- Kramer, Joel H;
- Koeppe, Robert;
- Kukull, Walter A;
- La Joie, Renaud;
- Mundada, Nidhi S;
- Murray, Melissa E;
- Nudelman, Kelly;
- Soleimani‐Meigooni, David N;
- Rumbaugh, Malia;
- Toga, Arthur W;
- Touroutoglou, Alexandra;
- Vemuri, Prashanthi;
- Atri, Alireza;
- Day, Gregory S;
- Duara, Ranjan;
- Graff‐Radford, Neill R;
- Honig, Lawrence S;
- Jones, David T;
- Masdeu, Joseph;
- Mendez, Mario F;
- Womack, Kyle;
- Musiek, Erik;
- Onyike, Chiadi U;
- Riddle, Meghan;
- Rogalski, Emily;
- Salloway, Steven;
- Sha, Sharon J;
- Turner, Raymond S;
- Wingo, Thomas S;
- Wolk, David A;
- Carrillo, Maria C;
- Dickerson, Bradford C;
- Rabinovici, Gil D;
- Apostolova, Liana G;
- Consortium, LEADS
Introduction
We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).Methods
Baseline NPS (Neuropsychiatric Inventory - Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups - amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70).Results
Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD.Discussion
Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.